CoChat

Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study

Open access
Hochmair, Maximilian J, Morabito, Alessandro, Hao, Desiree, Yang, Cheng-Ta, Soo, Ross A, Yang, James C-H, Gucalp, Rasim, Halmos, Balazs, Wang, Lara, Märten, Angela, Cufer, Tanja · 2019 · Future Oncology

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8–46.3) overall and 45.7 months (90% CI: 45.3–51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8–30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT03370770

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon-2019-0346

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 87

Metadata

Authors
Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., & Cufer, T.
Affiliations
  • Ludwig Boltzmann Institute for Lung Health (AT)
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • Tom Baker Cancer Center, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Chang Gung Memorial Hospital (TW)
  • National University Hospital (SG)
  • National Taiwan University Hospital (TW)
  • Albert Einstein College of Medicine (US)
  • Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA
  • Boehringer Ingelheim (Taiwan) (TW)
  • Boehringer Ingelheim (Germany) (DE)
  • University Clinic Golnik, University of Ljubljana, Ljubljana, Slovenia
Venue
Future Oncology
Published
2019-08-02
Volume
15
Issue
25
Pages
2905-2914
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W2965410028
Cited by
85
References
27
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 8 · 2022: 13 · 2021: 21 · 2020: 23 · 2019: 10
FWCI
12.31
Type
journal article
Language
en
Open access
Locations
  • Future Oncology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DiRROS repository (University of Maribor) (publishedVersion, cc-by-nc-nd)
Funders
  • Boehringer Ingelheim
  • AstraZeneca
  • Pfizer
  • Novartis
  • Takeda
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
afatinib, osimertinib, EGFR-mutant non-small cell lung cancer, T790M, time to treatment failure, overall survival, EGFR exon 19 deletion, L858R mutation, real-world evidence
MeSH terms
Afatinib, Acrylamides, Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Mutation, Pyrimidines, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study. https://app.cochat.ai/papers/10.2217/fon-2019-0346
The paper
Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., & Cufer, T. (2019). Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study. Future Oncology. https://doi.org/10.2217/fon-2019-0346

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.